Aptinyx Inc. (NASDAQ:APTX) Expected to Post Earnings of -$0.31 Per Share

Wall Street analysts forecast that Aptinyx Inc. (NASDAQ:APTXGet Rating) will post earnings per share of ($0.31) for the current quarter, Zacks reports. Zero analysts have made estimates for Aptinyx’s earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.37). Aptinyx posted earnings of ($0.22) per share during the same quarter last year, which suggests a negative year over year growth rate of 40.9%. The firm is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Aptinyx will report full year earnings of ($1.10) per share for the current year, with EPS estimates ranging from ($1.30) to ($1.01). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.84) per share, with EPS estimates ranging from ($1.24) to ($0.30). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Aptinyx.

Aptinyx (NASDAQ:APTXGet Rating) last announced its earnings results on Wednesday, March 23rd. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.06. During the same quarter in the previous year, the company posted ($0.20) earnings per share.

Several research analysts recently commented on APTX shares. Zacks Investment Research downgraded shares of Aptinyx from a “buy” rating to a “hold” rating in a research note on Friday. Truist Financial reduced their price target on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, April 8th. BMO Capital Markets reduced their price target on shares of Aptinyx from $12.00 to $6.00 in a research note on Friday, April 8th. HC Wainwright reduced their price target on shares of Aptinyx from $8.00 to $2.00 and set a “buy” rating on the stock in a research note on Thursday, April 14th. Finally, William Blair downgraded shares of Aptinyx from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 7th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $3.88.

A number of institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its holdings in shares of Aptinyx by 244.5% in the 2nd quarter. Royal Bank of Canada now owns 9,288 shares of the company’s stock valued at $26,000 after buying an additional 6,592 shares in the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Aptinyx in the 4th quarter valued at about $29,000. Blair William & Co. IL bought a new stake in shares of Aptinyx in the 4th quarter valued at about $51,000. Lindbrook Capital LLC bought a new stake in shares of Aptinyx in the 4th quarter valued at about $53,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Aptinyx in the 4th quarter valued at about $54,000. Institutional investors own 50.34% of the company’s stock.

Shares of APTX traded down $0.01 during midday trading on Friday, hitting $0.99. The stock had a trading volume of 186,530 shares, compared to its average volume of 935,238. Aptinyx has a 1 year low of $0.90 and a 1 year high of $4.73. The firm has a market cap of $67.18 million, a PE ratio of -0.89 and a beta of 1.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 20.18 and a quick ratio of 20.18. The stock’s 50 day moving average is $2.52 and its 200 day moving average is $2.57.

Aptinyx Company Profile (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

See Also

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.